Historically, we immunized children against diseases like polio that were a clear danger to them, but COVID-19 is usually mild in children. However, herd immunity is unlikely without vaccinating kids.
Articles on mRNA vaccines
Displaying 101 - 113 of 113 articles
Rollout of COVID-19 vaccines has begun. But getting the jab doesn’t mean abandoning masks, distancing and handwashing. Here’s why the current preventive measures must continue post-vaccine.
The best approach for protecting everyone’s health will require us to provide different vaccines to different people according to need and availability.
We should applaud drug companies for developing COVID-19 vaccines in record time, but let’s not be under any illusion about the profits that are motivating them.
Vaccine hesitancy is not new, but it has a new element: few people can remember the devastating impact of diseases such as smallpox and polio and it is hard to see the lives saved by vaccination.
Because Pfizer-BioNTech and Moderna vaccines have been developed in record time, many wonder whether companies cut corners or compromised safety.
Two pharma companies have announced early COVID-19 vaccine trial results with over 90 per cent effectiveness. What does that mean for getting back to normal?
Canada has set aside a total of 414 million doses of different types of vaccine. Some exploit known mechanisms, others are based on previously untested approaches.
Interim analysis of trial data isn’t unusual – but leaves us with many things we still need to find out.
Early analysis suggests this vaccine has an efficacy of over 90%. So if you took ten people who were going to get sick from COVID-19 and vaccinated them, only one would get sick.
Two more COVID-19 vaccines may now be on the cards for Australia, should they pass clinical trials. But, as with earlier vaccine deals, there are no guarantees.
So-called mRNA vaccines are among the frontrunners in the global race to design a COVID vaccine. But as a new technology, most nations, including Australia, lack the capacity to produce them at scale.
Results from phase 1 trials of a COVID-19 mRNA vaccine created a burst of optimism. But details the company failed to release suggest it is too early to speculate whether the vaccine is effective.
Top contributors
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Professor of Microbiology, School of Medicine, University of Washington
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Pediatric Infectious Diseases Fellow, University of Pittsburgh
-
Professor of Medicine, University of Virginia
-
Associate Professor of Biology, Rochester Institute of Technology
-
Senior Research Fellow in Global Health, University of Southampton
-
Bioengineer and Research Fellow, Monash University
-
Australia's Chief Scientist, Office of the Chief Scientist
-
Early Career Research Leader, Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University
-
Professor and Department Chair of Infectious Diseases and Microbiology, University of Pittsburgh
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Professor of Biomedical Sciences, Anglia Ruskin University